.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
McKesson
Daiichi Sankyo
Federal Trade Commission
Queensland Health
Healthtrust
Medtronic
Harvard Business School
QuintilesIMS

Generated: November 19, 2017

DrugPatentWatch Database Preview

J And J Consumer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for J AND J CONSUMER INC, and when can generic versions of J AND J CONSUMER INC drugs launch?

J AND J CONSUMER INC has twenty-eight approved drugs.

There are nine US patents protecting J AND J CONSUMER INC drugs.

There are one hundred and eleven patent family members on J AND J CONSUMER INC drugs in forty-three countries and thirteen supplementary protection certificates in seven countries.

Summary for J And J Consumer Inc

International Patents:111
US Patents:9
Tradenames:22
Ingredients:10
NDAs:28
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc
CHILDREN'S MOTRIN COLD
ibuprofen; pseudoephedrine hydrochloride
SUSPENSION;ORAL021128-001Aug 1, 2000OTCYesYes► Subscribe► Subscribe ► Subscribe
J And J Consumer Inc
NUPRIN
ibuprofen
TABLET;ORAL019012-002Jul 29, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-002Dec 17, 2007OTCYesYes► Subscribe► SubscribeY► Subscribe
J And J Consumer Inc
IBUPROFEN
ibuprofen
TABLET;ORAL070081-001Jun 16, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM A-D
loperamide hydrochloride
SOLUTION;ORAL019487-001Mar 1, 1988OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC ALLERGY
cetirizine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL022578-001Sep 3, 2010OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
SUDAFED 24 HOUR
pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020021-002Dec 15, 1992OTCYesYes► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC HIVES RELIEF
cetirizine hydrochloride
TABLET;ORAL019835-005Nov 16, 2007OTCYesNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET;ORAL020325-001Apr 28, 1995OTCYesNo► Subscribe► Subscribe► Subscribe
J And J Consumer Inc
ZYRTEC
cetirizine hydrochloride
SYRUP;ORAL020346-001Sep 27, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for J And J Consumer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-002Dec 17, 2007► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET;ORAL021140-001Nov 30, 2000► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET;ORAL021140-001Nov 30, 2000► Subscribe► Subscribe
J And J Consumer Inc
SUDAFED 24 HOUR
pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020021-002Dec 15, 1992► Subscribe► Subscribe
J And J Consumer Inc
PEPCID COMPLETE
calcium carbonate; famotidine; magnesium hydroxide
TABLET, CHEWABLE;ORAL020958-001Oct 16, 2000► Subscribe► Subscribe
J And J Consumer Inc
CHILDREN'S MOTRIN
ibuprofen
TABLET, CHEWABLE;ORAL020601-001Nov 15, 1996► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET;ORAL020325-001Apr 28, 1995► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM A-D
loperamide hydrochloride
SOLUTION;ORAL019487-001Mar 1, 1988► Subscribe► Subscribe
J And J Consumer Inc
PEPCID AC
famotidine
TABLET, CHEWABLE;ORAL020801-001Sep 24, 1998► Subscribe► Subscribe
J And J Consumer Inc
IMODIUM MULTI-SYMPTOM RELIEF
loperamide hydrochloride; simethicone
TABLET, CHEWABLE;ORAL020606-001Jun 26, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for J AND J CONSUMER INC drugs

Drugname Dosage Strength Tradename Submissiondate
cetirizine hydrochloride
Syrup5 mg/5 mL
ZYRTEC
3/19/2007
cetirizine hydrochloride
Chewable Tablets5 mg and 10 mg
ZYRTEC
3/25/2005
calcium carbonate/ famotadine/ magnesium hydroxide
Chewable Tablets800 mg/ 10 mg/ 165 mg (OTC)
PEPCID COMPLETE
11/1/2004

Non-Orange Book Patents for J And J Consumer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,060,730Rapidly absorbed liquid compositions► Subscribe
6,489,329 Pharmaceutical compositions for the treatment of rhinitis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for J And J Consumer Inc Drugs

Country Document Number Estimated Expiration
Spain2184293► Subscribe
Spain2324769► Subscribe
Cyprus1109238► Subscribe
Japan2004536829► Subscribe
Romania122476► Subscribe
Hungary0400386► Subscribe
World Intellectual Property Organization (WIPO)9901133► Subscribe
Russian Federation2004101231► Subscribe
Brazil9810495► Subscribe
United Kingdom9706842► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for J And J Consumer Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
01C/045Belgium► SubscribePRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
2008006,C0933372Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
C/GB08/018United Kingdom► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Cantor Fitzgerald
Healthtrust
Chinese Patent Office
US Army
Accenture
Federal Trade Commission
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot